GlassScriptPhysician profile
D'Ann Markert
NPI 1760517742
$1,610.26
in general payments reported to CMS, 2019-2025
18 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,375 · 2024: $20.78 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $404.86 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $356.33 | 2021-2025 | Breztri |
| Abbvie INC. | $184.93 | 2021-2024 | |
| Amgen INC. | $130.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $105.58 | 2021 | |
| Lilly USA, LLC | $79.38 | 2021 | |
| Glaxosmithkline, LLC. | $57.01 | 2021 | |
| Eisai INC. | $55.45 | 2021 | |
| Pfizer INC. | $51.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.80 | 2021 | |
| Esperion Therapeutics, INC. | $30.23 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.76 | 2021 | |
| Amarin Pharma, INC. | $18.40 | 2021 | |
| Dexcom, INC. | $17.44 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $14.63 | 2021 | |
| Merck Sharp & Dohme LLC | $11.94 | 2021 | |
| Allergan, INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw D'Ann Markert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.